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LETTERS TO THE EDITOR
Stable creatinine clearance
using large-dose HES versus
reduced GFR
To the editor: In a recent issue of Kidney Interna-
tional, Winkelmayer et al [1] reported postoperative renal
impairment after a relatively low dose of hydroxyethyl
starch (HES) 670/0.75 in patients with coronary artery
bypass graft (CABG). These data should be compared
with data from a randomized clinical trial recently pub-
lished by our group [2], which do not support the find-
ings by Winkelmayer et al, but in fact show preserved
renal function when a novel HES 130/0.4 specification
was administered in repetitive large doses in patients with
head injury. In addition, a study of Jungheinrich et al [3]
in volunteers with mild-to-severe renal impairment did
not reveal further deterioration of renal function after a
single HES 130/0.4 dose. These contrasting findings do
not surprise. Each different HES solution has its specific
physicochemical properties (molar substitution [MS],
pattern of hydroxyethylation [C2:C6 ratio], mean molec-
ular weight [Mw]) that determine the in vivo character-
istics. Unfavorable in vivo characteristics of mainly older
HES products with high Mw and high MS (hetastarches,
e.g., HES 450/0.7) are known to cause plasma accumula-
tion of macromolecules [4], which has been attributed to
impaired renal function and blood coagulation. There-
fore, physicochemical characteristics of new generation
HES solutions, such as HES 130/0.4, have been modified
and result in negligible plasma accumulation, preserved
renal function, and blood coagulation. Because physic-
ochemical characteristics appear to be critical to patient
safety we suggest that properties of HES products should
be considered before their use in the clinical setting, and
that findings with certain HES types must not be gener-
alized for other HES solutions.
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Reply from the Authors
Drs. Neff and Stocker point out that different prepa-
rations of hydroxyethyl starch (HES) might differ with
regard to their biologic actions, which is compatible with
our findings.They provide data from two manufacturer-
funded studies of a novel HES 130/0.4 product to support
the claim that HES (130/0.4) preserved renal function
in a randomized clinical trial. The cited study was con-
ducted in trauma patients randomized to either receive
HES (130/0.4) or HES (200/0.5) plus human albumin.
While there was no difference in renal function (mea-
sured by creatinine clearance) between the two regimens
during follow-up, the authors failed to disclose renal func-
tion at baseline, so that change of renal function cannot
be judged from the article. Also, the number of patients
studied was small (N = 15 + 16), so that the power to
detect any meaningful differences between these groups
was limited. We performed a power calculation of that
study (assuming a = 0.05, and SD = 20 mL/min) and
found that its power to detect a between-group difference
of 7 mL/min was only 15%, and only 9% for a within-
group comparison. The same argument pertains to the
second study they cite (N = 19), which was conducted
in volunteers with stable renal function, a setting that is
probably not representative of a surgery or intensive care
situation. The data from the studies cited are therefore
of very limited use regarding a possible association be-
tween HES use and renal function. While different HES
preparations may have different effects on renal function,
unless this is shown in a sufficiently well powered study,
the concern of adverse outcomes in HES recipients re-
mains unresolved.
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Clinical acid-base disorders:
Traditional versus “new”
analytical models
To the Editor: I have taught acid-base physiology to
medical students, residents, fellows, and practicing clini-
cians for many years. Although this is often an initially
confusing topic for many of these individuals, after sev-
eral lectures, a few case examples, and some practical ex-
perience, most are soon able to successfully dissect even
very complex mixed acid-base disorders. Measurements
of arterial pH, pCO2, and calculated or measured HCO3,
together with calculation of the anion gap and knowl-
edge of several empiric compensation rules, allows most
clinicians to fully explain virtually all acid-base pertur-
bations. Over the past few decades a number of “new”
approaches have been proposed, including “whole-blood
buffer base” of Singer and Hastings and “standard bicar-
bonate” and “base excess” of Astrup. In a recent per-
spective discussion, Corey [1] claims that a now classic
editorial by Schwartz and Relman [2] concluded “ . . . base
excess has conquered its rivals to form the cornerstone
of standard clinical acid-base chemistry.” The editorial
actually says the opposite! Indeed, it concludes that “the
traditional measurements of pH, pCO2, and plasma bi-
carbonate concentration continue to be the most reliable
biochemical guides in the analysis of acid-base distur-
bances.” More recently, a number of clinicians, including
Corey, have suggested we adopt the “Stewart” approach,
which analyzes three “independent variables:” “strong
ion difference,” “total weak acids,” and pCO2. The
Stewart approach may be mathematically correct but
I believe it adds little to the clinical interpretation of acid-
base disorders and markedly increases complexity.
It is claimed that the “Stewart” approach elucidates
certain complex disorders, yet I have still not encountered
a case where this is true. For example, Corey presents the
following case: “a critically ill patient with septic shock
and multiple organ failure . . . on cardiopressors, mechan-
ical ventilation, antibiotics, and large volumes of normal
saline. Na 130, K 3.0, Cl 111, albumin 1.5 g%, phosphate
2.0 mg%, HCO3 = 9.25, pCO2 = 30, pH = 7.1.” My in-
terpretation is—metabolic acidosis with inadequate res-
piratory compensation (respiratory acidosis). The anion
gap is about 10 (I prefer the equation AG = Na – (HCO3
+ Cl)). His albumin is reduced to 1.5 g% so his “base-
line” anion gap should be about 4. The AG is therefore
increased by about 6 and would account for a portion
of the fall in HCO3 (from 24 to about 18). His chlo-
ride concentration is also increased relative to sodium
and explains the rest of the fall in HCO3 (from 18 to 9).
The “traditional” approach therefore says the patient has
an anion gap metabolic acidosis (probably lactic), a hy-
perchloremic metabolic acidosis (possibly diarrhea, renal
tubular, and/or a component of “NaCl expansion”), and
respiratory acidosis due to lung and/or brain dysfunction.
Therefore, I strongly disagree with Corey’s statement
“ . . . that the traditional model offers no further insight
into the mechanism of the acid-base disorder.” Indeed,
what does the “Stewart” approach add to my analysis?
It may be mathematically correct, but it is bound to in-
troduce further confusion to an already confusing area
of medicine. Einstein said “Make everything as simple as
possible, but not simpler,” and I would add a corollary,
“Don’t needlessly make things more complex than they
need to be.”
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Reply from the Author
I would like to thank Professor Emmett for his com-
ments. First, he concedes that the Stewart approach is
sound mathematically. Second, as a proponent of the
“Boston” school he implies that base excess is an im-
perfect parameter to describe acid-base balance. Third,
he demonstrates that the anion gap may be unhelpful
if uncorrected for serum albumin. Lastly, he invokes
Stewart’s Strong Ion Difference (“chloride concentration
is also increased relative to sodium”) to explain “the rest
in the fall in HCO3” in the problem case under discussion.
In essence, I believe that Professor Emmett has summa-
rized quite nicely the major thesis of my review.
